Chromosomal abnormalities in patients with non-cutaneous T-cell non-Hodgkin's lymphoma |
| |
| Affiliation: | 1. Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.;2. Department of Pediatrics, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.;3. Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.;4. Clinical Fellow, Netherlands Cancer Foundation Koningin Wilhelmina Fonds The Netherlands;1. Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China;2. State Key Laboratory of Trauma, Burns and Combined Injury, Army Medical University, Chongqing, 400037, China;1. Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;2. Institut Català d''Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain;3. Ankara University, Ankara, Turkey;4. Università degli studi di Perugia, Perugia, Italy;5. Azienda Ospedaliera Papa Giovanni XXIII, Unità Operativa di Ematologia, Bergamo, Italy;6. Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway;7. K G Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway;8. East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, UK;9. Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;10. Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada;11. University of Lille, Centre Hospitalier Universitaire Lille, Service des Maladies du Sang, Lille, France;12. Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain;13. National Hospital Organization Okayama Medical Center, Okayama, Japan;14. Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland;15. Cancer Trials Ireland, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland;p. Erasmus MC Cancer Institute, Rotterdam, Netherlands;q. Medical University of Lodz, Lodz, Poland;r. Pirogov Russian National Research Medical University, Moscow, Russia;s. Department of Hematology, King''s College London, London, UK;t. Celgene Corporation, Summit, NJ, USA;u. Celgene International, Boudry, Switzerland;v. National and Kapodistrian University of Athens, Athens, Greece;1. Duke Cancer Institute and Center for Genomic and Computational Biology, Duke University, Durham, NC, USA;2. Department of Medicine, Duke University Medical Center, Durham, NC, USA;3. Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland;4. Herlev and Gentofte Hospital, Copenhagen University, Herlev, Denmark;5. Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA;6. Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA;7. Winship Cancer Institute, Emory University, Atlanta, GA, USA;8. Hadassah-Hebrew University Medical Center, Jerusalem, Israel;9. Barts Cancer Institute of Queen Mary University of London, London, UK;10. Pathology, Indiana University, Indianapolis, IN, USA;11. Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA;12. Queen Mary Hospital, University of Hong Kong, Hong Kong;13. Tufts University Medical Center, Boston, MA, USA;14. Tata Memorial Center, Mumbai, India;15. Vanderbilt University Medical Center, Nashville, TN, USA;16. MD Anderson Cancer Center, Houston, TX, USA;17. Columbia-Presbyterian Hospital, New York, NY, USA;18. Northwestern University Medical School, Chicago, IL, USA;19. National Cancer Institute, Bethesda, MD, USA;20. Hudson Alpha Institute for Biotechnology, Huntsville, AL, USA;21. Department of Statistical Science, Duke University, Durham, NC, USA;1. Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305, USA;2. Department of Biomedical Data Science, Stanford University, Stanford, CA 94305, USA;3. Stanford Center for Biomedical Informatics Research, Department of Medicine, Stanford University, Stanford, CA 94305, USA;4. Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305, USA;5. Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA;6. Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;7. KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;8. Institute for Stem Cell Biology & Regenerative Medicine, Stanford University, Stanford, CA 94305, USA;9. Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA;1. Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA;2. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA;3. Department of Genetics, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA;1. Department of Biochemistry, University of Washington, Seattle, WA 98195, USA;2. Institute for Protein Design, University of Washington, Seattle, WA 98195, USA;3. TopoGene Inc., Seattle, WA 98195, USA;4. Graduate Program in Biological Physics, Structure and Design, University of Washington, Seattle, WA, USA;5. Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA;6. Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA 98195, USA;7. Graduate Programs in Medical Scientist Training and Neuroscience, University of Washington, Seattle, WA, USA;8. Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA |
| |
| Abstract: | In contrast to non-Hodgkin's lymphomas (NHL) with a B-cell phenotype, almost no data have been reported dealing with correlations between chromosomal abnormalities and characteristics of the disease in patients with T-cell NHL. In a retrospective analysis we studied all patients with a non-cutaneous T-cell NHL and chromosomal abnormalities that were evaluated at our institution; 20 patients could be identified. Numerical abnormalities involving chromosomes 3, 4, 5, 22 and X were observed most frequently. Structural abnormalities involved mainly the breakpoints 1q22–25, 6q23 and 11q13. There appeared to be an association between +7 breakpoints 2p23–24, 4p14–15, 8q21 and the presence of extranodal disease. All patients with +7 had a diffuse mixed histology. Patients with +2, +3, +11, +17, +18, +20 or breakpoint 1q22–25 had an immunoblastic lymphoma and patients with breakpoints 9q32–34 or 14q12 had a lymphoblastic lymphoma. No correlations were observed between chromosomal abnormalities and response to therapy, survival or phenotypic markers. Abnormalities involving the chromosomes containing the T-cell receptor genes and T-cell markers were infrequent. Several breakpoints were identified that correlate with already described oncogenes. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
